28 terminated. 28 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 28 | Terminated 28 |
| Phase 2 | 4 | Terminated 4 |
Follow Multiple Myeloma: new trials by email Literature Review of Multiple Myeloma trials Research Report on Multiple Myeloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy Allogeneic Stem Cells, carfilzomib/lenalidomide/dexamethasone (KRD), elotuzumab/lenalidomide/dexamethasone (ERD) - Multiple Myeloma | Phase 3 | Terminated | Universitätsklinikum Hamburg-Eppendorf | 28 | 2023-03-03 | 2026-01-05 |
| Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma Melflufen, Dexamethasone, Daratumumab - Relapsed Multiple Myeloma, Relapsed-Refractory Multiple Myeloma | Phase 3 | Terminated | Oncopeptides AB | 54 | 2020-12-21 | 2023-06-08 |
| Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin Belantamab mafodotin - Multiple Myeloma | Phase 3 | Terminated | GlaxoSmithKline | 16 | 2020-12-21 | 2023-12-13 |
| A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide Melflufen, Pomalidomide, Dexamethasone - Multiple Myeloma | Phase 3 | Terminated | Oncopeptides AB | 495 | 2017-06-12 | 2024-01-30 |
| Pom-dex Versus Pom-Cyclo-dex in MM Patients With Biochemical or Clinical Relapse, During Lena Maintenance Treatment Pomalidomide, Cyclophosphamide, Dexamethasone - Multiple Myeloma | Phase 3 | Terminated | Fondazione EMN Italy Onlus | 9 | 2016-02-18 | 2021-03-10 |
| BiRd vs. Rd as Initial Therapy in Multiple Myeloma Clarithromycin, Lenalidomide, Dexamethasone - Multiple Myeloma | Phase 3 | Terminated | Weill Medical College of Cornell University | 12 | 2016-02-01 | 2023-06-05 |
| Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183) Pembrolizumab, Pomalidomide, Dexamethasone - Multiple Myeloma | Phase 3 | Terminated | Merck Sharp & Dohme LLC | 251 | 2015-10-19 | 2021-10-08 |
| Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185) Pembrolizumab, Lenalidomide, Dexamethasone - Multiple Myeloma | Phase 3 | Terminated | Merck Sharp & Dohme LLC | 310 | 2015-10-19 | 2021-07-20 |
| Treatment Optimization in Patients With Untreated Multiple Myeloma Lenalidomide, Placebo - Multiple Myeloma | Phase 2 / Phase 3 | Terminated | Dr. med. Lars-Olof Muegge | 85 | 2013-08-01 | 2019-01-16 |
| Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide plerixafor, filgrastim - Refractory Multiple Myeloma | Phase 3 | Terminated | Case Comprehensive Cancer Center | 9 | 2011-07-01 | 2014-08-06 |
| A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma Masitinib, Placebo, Bortezomib - Multiple Myeloma | Phase 3 | Terminated | AB Science | 147 | 2011-05-01 | 2018-12-19 |
| Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients Perifosine, Perifosine Placebo, Bortezomib - Multiple Myeloma | Phase 3 | Terminated | AEterna Zentaris | 135 | 2009-12-01 | 2018-02-09 |
| Randomized Study of Velcade-based Regimen With Autologous Stem Cell Transplantation in Newly-diagnosed Myeloma Patients velcade - Multiple Myeloma | Phase 2 / Phase 3 | Terminated | Shanghai Jiao Tong University School of Medicine | 23 | 2009-08-01 | 2016-09-08 |
| Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor Donor lymphocyte preparation depleted of host functional alloreactive T-cells - Myeloid Leukemia, Lymphoblastic Leukemia | Phase 2 / Phase 3 | Terminated | Kiadis Pharma | 40 | 2009-08-01 | 2021-06-14 |
| Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies Fludarabine, Total Body Irradiation, Infusion of Stem Cells - Multiple Myeloma, CLL / SLL | Phase 2 / Phase 3 | Terminated | University of Alabama at Birmingham | 5 | 2008-07-01 | 2017-07-24 |
| Preemptive Strike With Bortezomib in Multiple Myeloma Patients Bortezomib - Multiple Myeloma | Phase 3 | Terminated | University of Arkansas | 10 | 2008-02-01 | 2017-11-20 |
| Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone bortezomib, lenalidomide, dexamethasone - Stage I Multiple Myeloma, Stage II Multiple Myeloma | Phase 3 | Terminated | National Cancer Institute (NCI) | 48 | 2007-09-01 | 2015-06-26 |
| Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2 Velcade, Thalidomide, and Dexamethasone, Velcade, Melphalan, and Dexamethasone - Multiple Myeloma | Phase 3 | Terminated | University of Arkansas | 5 | 2006-08-01 | 2011-08-12 |
| UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide Interim/Maintenance Dexamethasone, Induction/Consolidation Dexamethasone, Induction/Consolidation Cisplatin - Multiple Myeloma | Phase 3 | Terminated | University of Arkansas | 20 | 2006-07-01 | 2017-11-20 |
| Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant moxifloxacin hydrochloride, Placebo - Breast Cancer, Chronic Myeloproliferative Disorders | Phase 3 | Terminated | OHSU Knight Cancer Institute | 240 | 2006-05-01 | 2017-05-09 |
Showing 20 of 28. Sign in to see all of them.
Lymphoma, Mantle-Cell (3) · Lymphoma, Non-Hodgkin (3) · Myeloproliferative Disorders (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Blast Crisis (2) · Breast Neoplasms (2) · Burkitt Lymphoma (2) · Carcinoma, Ovarian Epithelial (2) · Graft vs Host Disease (2) · Hematologic Neoplasms (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Leukemia, Myeloid, Accelerated Phase (2) · Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (2) · Leukemia, Myeloid, Chronic-Phase (2)
Blood Protein Disorders (28) · Cardiovascular Diseases (28) · Hematologic Diseases (28) · Hemic and Lymphatic Diseases (28) · Hemorrhagic Disorders (28) · Hemostatic Disorders (28) · Immune System Diseases (28) · Immunoproliferative Disorders (28) · Lymphoproliferative Disorders (28) · Neoplasms by Histologic Type (28) · Paraproteinemias (28) · Vascular Diseases (28) · Neoplasms (27) · Neoplasms, Plasma Cell (27) · Disease Attributes (5)
Dexamethasone (13) · Bortezomib (8) · Calcium Dobesilate (5) · Thalidomide (5) · Lenalidomide (4) · pomalidomide (4) · Zoledronic Acid (3) · Cyclophosphamide (2) · Filgrastim (2) · Granulocyte Colony-Stimulating Factor (2) · L-melphalanyl-p-L-fluorophenylalanine ethyl ester (2) · Melphalan (2) · daratumumab (2) · dexamethasone acetate (2) · melflufen (2)
University of Arkansas (3) · Merck Sharp & Dohme LLC (2) · Oncopeptides AB (2) · AB Science (1) · AEterna Zentaris (1) · Case Comprehensive Cancer Center (1) · Central Hospital, Nancy, France (1) · Dr. med. Lars-Olof Muegge (1) · European Society for Blood and Marrow Transplantation (1) · Fondazione EMN Italy Onlus (1) · GlaxoSmithKline (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Hoffmann-La Roche (1) · Kiadis Pharma (1) · Martin, Paul (1)
United States (17) · Germany (7) · Canada (4) · Czechia (4) · France (4) · Italy (4) · Belgium (3) · Israel (3) · Russia (3) · Spain (3) · United Kingdom (3) · Austria (2) · Greece (2) · Hungary (2) · Netherlands (2)
Bart Barlogie, MD, PhD (2) · Andrea Velardi, MD (1) · Annamaria Brioli, MD (1) · Bertrand Arnulf, MD (1) · Cyrille Hulin, MD (1) · Denis-Claude Roy, MD (1) · Francis Ayuk, Prof. Dr. med. (1) · Frits van Rhee, MD, PhD (1) · Hien Duong, MD (1) · Hillard Lazarus, MD (1) · Jorge Monge, MD (1) · Joseph Bubalo, PharmD, BCPS, BCOP (1)
PMID 19270260, PMID 22674807, PMID 31327687, PMID 31327689, PMID 33086159, PMID 35032434, PMID 37355418, PMID 37646657, PMID 37646660, PMID 38426292, PMID 39865222, PMID 40338596, PMID 41437395
2015 (2), 2005 (1), 2019 (1), P30CA069533 (1), U10CA021115 (1), U10CA032102 (1), U10CA180820 (1)